Basic Galaxy Tutorial

• RNA-Seq tutorial based on Trapnell et al. (2012) Nature Protocols

In this tutorial we cover the concepts of RNA-Seq differential gene expression (DGE) analysis using a very small synthetic dataset from a well studied organism.

Advanced Galaxy Tutorial

• RNA-Seq (Advanced) Tutorial

In this tutorial we compare the performance of three statistically-based differential expression tools:

* CuffDiff

* EdgeR

* DESeq2

Advanced Command Line Tutorial

• Graphical Output with CummeRbund introduces some basic commands using the cummeRbund package of the R programming language

You will need to install R, RStudio and cummeRbund on your PC (explained in the Tutorial). You will learn how to produce graphical output from RNA-Seq analysis previously done using a Cuffdiff analysis.

Variant Detection

Basic Galaxy Tutorial

• Variant Detection tutorial

In this tutorial we cover the concepts of detecting small variants (SNVs and indels) in human genomic DNA using a small set of reads from chromosome 22.

Advanced Galaxy Tutorial

• Variant Detection (Advanced) Tutorial

In this tutorial we compare the performance of three statistically-based variant detection tools:

* SAMtools: Mpileup

* GATK: Unified Genotyper

* FreeBayes

Each of these tools takes as its input a BAM file of aligned reads and generates a list of likely variants in VCF format

Pipelines are for those who are comfortable with using the UNIX command line; and often allow more control over branching and iteration logic.

• WGS/exome GATK-based variant calling pipeline

This is a basic variant-calling and annotation pipeline developed at the Victorian Life Sciences Computation Initiative (VLSCI), University of Melbourne. It is based around BWA, GATK and ENSEMBL and was originally designed for human (or similar) data. The master branch is configured for WGS data; there is an exome branch configured for variant calling in exome data.

To run the pipeline you will need Rubra: https://github.com/bjpop/rubra. Rubra uses the python Ruffus library: http://www.ruffus.org.uk/.

Protocols

• Familial Variant Calling

In this protocol we discuss and outline the process of calling familial related mutations.

• Somatic Variant Calling

In this protocol we discuss and outline the process of identifying somatic variants or mutations.

Assembly

Basic Galaxy Tutorial

• Genome assembly tutorial

In this tutorial we carry out de novo assembly of a microbial genome. We have also written a De novo Genome Assembly for Illumina Data Protocol for a more generic description of the method.

Protocol

• De novo Genome Assembly for Illumina Data

In this protocol we discuss and outline the process of de novo assembly for small to medium sized genomes. Use our Genome assembly tutorial to learn a specific case of using Galaxy to carry out de novo assembly of a microbial genome.

Small RNAs

Basic Galaxy Tutorial

• Quality control for small RNA

This tutorial covers initial steps of the workflow for analysis of short RNA expression such as a quality control of the raw reads, processing of the raw reads for the subsequent analysis and initial quality assessment of the library.

ChIP Seq

Protocol

• ChIP-Seq

In this protocol we discuss ChIP-Seq: a method to analyze the interaction between proteins and DNA.

Amplicons

Protocol

• Amplicon Alignment

In this protocol we discuss and outline the process of aligning custom amplicons using primers for high precision.

Learn Galaxy

Introduction to Galaxy, for those who are very new to Galaxy.

Using Histories and Workflows, for those with some Galaxy knowledge.

The Galaxy project website has many tutorials and screencasts about using Galaxy and the tools, and developing new tools.

Address of the bookmark: https://genome.edu.au/wiki/Learn

More at https://leidosbiomed.csod.com/ats/careersite/jobdetails.aspx?site=4&c=leidosbiomed&id=2040

More at
https://zfin.org/ZDB-LAB-110408-1
http://www.imcb.a-star.edu.sg/php/venkatesh.php

Link @ http://bioinf.boku.ac.at/

Faculty facilitator/Founder Director for two start-up companies (Leadinvent incubated at IIT, Delhi from 2006-2009 & Novoinformatics, under incubation at IIT Delhi since 2011).

Research Interest
Genome Analysis, Protein Structure Prediction and Drug Design.

Link @ http://www.scfbio-iitd.res.in/

Genomics England will play a key role in building on the UK’s long track record as leader in medical science advances to push the boundaries by unlocking the power of DNA data. The UK will become the first ever country to introduce this technology in its mainstream health system – leading the global race for better tests, better drugs and above all better, more personalised care.

http://www.genomicsengland.co.uk/100k-genome-project/

SciGenom Research Foundation (SGRF) and Institute of Genomics and Integrative Biology (IGIB) are pleased to host the Next-Generation Sequencing and Bioinformatics for Genomics & Healthcare conference.

In the ten years since the first human reference genome was completed for US$3 billion the sequencing technologies have radically changed leading to great reduction in sequencing cost. Today a human genome can be sequenced for under US$ 5000 in less than two weeks. It is expected that by the end of 2015 the cost of sequencing a human genome will drop to below thousand dollars. The next generation sequencing technologies over the past five years have enabled a large number of genomic studies that impact human health and disease. Also, this has made possible the growth of microbial, animal and plant genomics studies. While the data production has increased at a rapid pace challenges remain in analyzing and understanding the data. The conference will cover the next generation sequencing (NGS) technologies, bioinformatics for NGS and applications of NGS in many areas including personalized medicine.

For more info : http://www.scigenomconferences.com/2013/default.php

Dr Altan Kara is a Bioinformatics specialist at the faculty of Gene Engineering and Biotechnology Institute at TUBITAK MAM Research Center. His research interest revolves around the cancer informatics and computational aided-drug design. I applaud Dr Altan for clearly setting out both his expectations of people that join his lab/university in addition to listing his responsibilities to his research members at TUBITAK MAM Research Institüte. Hopefully, this interview will prove useful to others in the field, especially to those who are just starting their bioinformatics careers.

You can find out more about Dr Altan by visiting his (well documented) lab page (http://gmbe.mam.tubitak.gov.tr/en) and BOL page http://bioinformaticsonline.com/profile/altan . And now, on to the BOL:“Tryst with a Bioinformatician” interview series ...

• What push you to join Computational Biology/Bioinformatics?

According to me, bioinformatics is the center of modern biological research and if a researcher wants to discover new biological insights by evaluating the globally produced biological data to derivate unified solutions for specific biological problems, learning bioinformatics is the only way to achieve this goal.

• What fascinates you about Computational Biology/Bioinformatics?

It's flexibility. As well known, there are highly diverse and complex biological questions are waiting to be enlightened and it's impossible to bring solutions to this diversity by using similar approaches. Thus, the employed method has to be unique for the targeted biological problem and by using bioinformatics tools this can be easily achieved. 

• What is the one word you would use to describe yourself?

Bioinformatician. :)

• Can you please describe your research work in a nutshell for BOL users.

At my current Institute, I am working in the field of cancer bioinformatics. Briefly, the overall aim of the project which I am working for (AKMARK (Project CODE:5153403)) is, applying a bioinformatics-supported genome, transcriptome, proteome, and metabolome analysis to reveal the molecular profile of the disease through an integrated approach, and to develop an early diagnosis and scanning kit based on this profile. Alterations in the gene, transcript, protein, and metabolite profiles between normal tissue, normal tissue adjoined to the tumor (reactive stroma), tumor tissue, lymph node metastasis, and blood samples taken from the same patient and the reflection of these changes in some other selected body fluids will be revealed within the scope of the project. The molecular structures involved in the development and progression of NSCLC will be determined and relations with the clinical, tumor-node-metastasis (TNM) staging and histology will be made. The development of a diagnostic kit for immediate clinical purposes and an electrochemical biosensor for quick on-site applications are targeted through the development of a number of antibody and aptamer formed against the most specific biomarker selected from the panel.

• Is there anything else we should know about you and your research?

Besides AKMARK, I am also in preparation of having a side project that aims for the development of a computational method to design inhibitors for prokaryotic two-component systems. In this project, I will be in collaboration with Prof. Maria Kontoyianni, SIUE: Southern Illinois University Edwardsville, School of Pharmacy.

• What was your greatest scientific disappointment in life till now?

So far I do not experience any memorable scientific disappointment in my life. :)

• What major research challenges and problems did you face yet? How did you handle them?

The major challenge which I faced so far in my scientific career was predicting the interaction between the prokaryotic two-component proteins. To be able to accurately predict the interactions between these proteins, I create a meta-predictor by using a support vector machine. By using this technique I integrated six different protein-protein interaction methods in a way to cover disadvantage of one method with the advantage of another one. The meta-predictor which I developed during this work is accessible via http://metapred2cs.ibers.aber.ac.uk/ and for more detailed information about the system the articles with the PMID IDs; PMID: 27378293 and PMID: 26384938 can be read.

• What's your all-time favourite bioinformatics package, and why?

For me, the best bioinformatics package is R/Bioconductor. The reason why I like this package is, it provides lots of useful tools for comprehensive analysis and comparison of high-throughput experimental data in an integrated manner and besides lots of the packages it provides, it is open source and also open for development. As a result, it provides strong and flexible ways to do science.

• In bioinformatics, do you see yourself in which of the following roles-scientist, analyst, developer, engineer or pure academician?

Scientist / Developer.

• What will you like to accomplish in next five years / ten years?

For my current research, I would like to design a pipeline to automatically integrate and analyse omics data for cancer research which will be specifically aiming for biomarker and novel drug target discovery. In addition to this, I also like to develop another pipeline for prokaryotic TCS protein structure prediction and inhibitor design.

• When you will be retired, what would you tell next generation bioinformaticians?

Bioinformatics is not all about scripting and researchers who study in this field should never expect a tool to do their analyses for them. Besides computational skills, a bioinformatician must have a strong biological background in his/her research area which will allow them to understand if anything went wrong during their run by only looking at the results instead of just blindly trusting the output of the bioinformatics tools.

• What you always miss in bioinformatics when you will no longer working in this field?

Bioinformatics is open to doing multi-discipliner research with scientists all around the world. As a result, while I studying in this field I can interactively learn a lot from wide range research community. I think this is the one thing which I will miss the most.

• If there will be bioinformatics company owned by you in future, What are your company focus and aim?

With the increasing amount of data in databases, there is already a massive need for effective methods to eliminate the manipulated data and reach to clean/useful information. As days pass, the requirement of data mining will be the first step of any research project. For this reason, the major goal of my bioinformatics company will be developing effective tools to eliminate manipulated datasets and information that exist in the literature and provide trustworthy clean information/datasets for researchers.

• How much bioinformatics change in 2050, according to your wild imagination?

Bioinformatics is a field that constantly and dynamically changes. As the bioinformatics progress, new tools and methods become available and they provide a better application of existing methods or totally new methods that offer an alternative solution to various biological problems. A long with these updates, developers also provide easy to use GUIs for most of the tools. Considering this, if the field carries on developing like this, every single researcher with a strong biological background can be able to perform bioinformatics analyses by him/herself without needing a professional help. As a result, almost all of the bioinformaticians will be responsible just for development of new methods/tools.

• What would one piece of advice you give someone who's trying to reinvent themselves and enter into bioinformatics sector?

Bioinformatics is a wide field with a lot of career options. Thus, if a researcher likes to step into this field first he/she should be clear about the branch of the bioinformatics they like to study in. Following to this decision they should first learn at least one programing language and investigate the ways of how other researcher employed that language in their researches and WHY? A researcher, in this field, should never create and use copy paste scripts but always must understand WHY the other researcher worked in that way. Knowing the answer of this question is the only way to learn bioinformatics. Besides, a researcher in the field of bioinformatics (from any branch) must always be good about the environmental control. In other words, one should always easily control input output directories, modify files or directories, annotate and modify employed scripts during the research and should not allow any confusion during the different stages of the research. Finally, they should not blindly trust the output of a tool/software but do a benchmarking test for each of the tools which they decided to utilise in their research. In addition to this, even if the tools pass the benchmarking, researchers should have a good biological background in their field to tell if anything when wrong during the process by only looking the output(s) of the employed pipelines/packages/tools.  

Candidates must have: a PhD degree in statistics, biostatistics or bioinformatics, extensive experience in analyzing high-dimensional data (microarray, SNP, CNVs) and of validation approaches. In addition, experience in penalized regression methods, data base manipulation; and strong programming skills in order to conduct Monte Carlo studies and applications (R). Candidate must have excellent communication skills (verbal, written and presentation), a strong proficiency in Linux system.

This position is available immediately and will be filled as soon as possible. Appointment could be extended beyond the first year based on additional funding.

For more information about the Department of Biostatistics and Bioinformatics, please visit our website: http://www.biostat.duke.edu.

For more info: http://biostat.duke.edu/sites/biostat.duke.edu/files/Halabi%20-%20Postdoc%20Job%20Posting%202013%20updated.pdf

Duke University is an Equal Opportunity/Affirmative Action Employer.